BridgeBio is significantly boosted this development of an novel therapy for ATTR-CM, employing the compound. Initial clinical data suggests promising outcomes for individuals suffering with the serious illness. This https://attrcm081860.blogtov.com/22828497/bridgebio-progresses-cardiac-amyloidosis-management-using-the-therapy